TheraRadar
Data updated: Jul 17, 2026

METHOTREXATE PRESERVATIVE FREE (methotrexate sodium) · Fresenius Kabi

Oncology Approved 1959-08-10

METHOTREXATE PRESERVATIVE FREE is FDA-approved to treat 6 conditions (same as METHOTREXATE SODIUM).

4
Indications
--
Phase 3 Trials
66
Years on Market

Details

Status
Prescription
First Approved
1959-08-10
Routes
INJECTION
Dosage Forms
INJECTABLE

Companies

Active Ingredient: METHOTREXATE SODIUM

METHOTREXATE PRESERVATIVE FREE Approval History

1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
235 FDA actions from 1959 to 2025 · 2 indication expansions
May 2025 SUPPL
Label · Labeling
Aug 2024 SUPPL
Label · Labeling
Nov 2023 SUPPL
Mfg · Manufacturing (CMC)

What METHOTREXATE PRESERVATIVE FREE Treats

6 indications

METHOTREXATE PRESERVATIVE FREE is approved for 6 conditions since its original approval in 1959. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Acute lymphoblastic leukemia (ALL)
  • Mycosis fungoides (cutaneous T-cell lymphoma)
  • Relapsed or refractory non-Hodgkin lymphoma
  • Rheumatoid arthritis
  • Polyarticular juvenile idiopathic arthritis (pJIA)
  • Severe psoriasis

Same approved indications as METHOTREXATE SODIUM (same active ingredient).

Source: FDA Label

Fresenius Kabi's other novel FDA approvals

Other CDER-designated drugs from the same sponsor (2016–2025).

📋

Clinical Trial Registry

3 trials
Trial Sponsor ID Phase Status Title
NCT02143414 results posted NCI-2014-01047 NCI-2014-01047, SWOG-S1318 Ph 2 active not recruiting Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia
NCT06354439 EcZOL 77015224.6.1001.5327 Ph 4 recruiting Use of Letrozole for Ectopic Pregnancy
NCT05575297 MRFI Ph 1 completed A Drug-drug Interaction Study to Evaluate the Effect of Rifampicin and Febuxostat on the Pharmacokinetics of Methotrexate in Healthy Subjects
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

METHOTREXATE PRESERVATIVE FREE FDA Label Details

Indications & Usage

FDA Label (PDF)

METHOTREXATE PRESERVATIVE FREE is FDA-approved to treat 6 conditions — same approved indications as METHOTREXATE SODIUM.

Track METHOTREXATE PRESERVATIVE FREE with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.